Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TNFSF11 | O14788 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | RORC | P51449 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12810538 | 0.86 | MAPK1 (0.44) | MAPK1TNFSF11RORCALDH1A1CXCR4 | |
| SCHEMBL1413604 | 0.81 | LMNA (0.50) | TNFSF11SMN1; SMN2ALDH1A1CXCR4PLK1 | |
| SCHEMBL1413693 | 0.80 | ALDH1A1 (0.50) | TNFSF11ALDH1A1CXCR4PLK1TNF | |
| SCHEMBL1413569 | 0.80 | HTR6 (0.55) | RORCALDH1A1CXCR4LMNAKMT2A | |
| SCHEMBL1413330 | 0.80 | LMNA (0.60) | TNFSF11SMN1; SMN2RORCALDH1A1CXCR4 | |
| SCHEMBL1413818 | 0.79 | HTR6 (0.54) | RORCALDH1A1CXCR4LMNAKMT2A | |
| SCHEMBL1413646 | 0.79 | HTR6 (0.53) | ALDH1A1CXCR4LMNAKMT2AMEN1 | |
| SCHEMBL5411264 | 0.78 | HTR6 (0.56) | RORCALDH1A1CXCR4LMNAKMT2A | |
| SCHEMBL1413705 | 0.78 | CXCR4 (0.54) | RORCALDH1A1CXCR4PLK1LMNA | |
| SCHEMBL1413829 | 0.77 | HTR6 (0.52) | ALDH1A1CXCR4LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1699761-B1 | CB1 MODULATOR COMPOUNDS | LILLY CO ELI (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7595339-B2 | CB1 modulator compounds | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080287504-A1 | CB1 MODULATOR COMPOUNDS | ALLEN JENNIFER REBECCA | 2008-11-20 | — | — | US | disclosed |
| US-7276516-B2 | CB1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088018-A1 | Cb1 antagonist compounds | CNR1, CNR2, CHRNA5 | MAPK1 420/4885TNFSF11 137/4885SMN1; SMN2 546/4885 |
| US-20080287504-A1 | CB1 MODULATOR COMPOUNDS | CNR1, CNR2, MAG | MAPK1 389/4885TNFSF11 122/4885SMN1; SMN2 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.